Reductive Metabolism of the Nitroimidazole-Based Hypoxia-Selective Cytotoxin NLCQ-1 (NSC 709257)

Oncology Research

Volumn 14, Issue 1, 2003, Pages 21-29

  Papadopoulou, Maria V ^a   Ji, Ming ^a   Rao, Mira K ^a   Bloomer, William D ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Bioreductive drug; Enzymatic reduction; Hypoxic cytotoxin; NLCQ 1

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; ADENOSINE 2' PHOSPHATE; CYTOCHROME B5 REDUCTASE; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 REDUCTASE; CYTOTOXIN; HYDROXYMERCURIBENZOIC ACID; MICROSOME ENZYME; NITROIMIDAZOLE DERIVATIVE; NLCQ 1; NSC 709257; PRODRUG; PROPYLTHIOURACIL; RECOMBINANT ENZYME; RECOMBINANT REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ADOLESCENT; AEROBIC METABOLISM; ANIMAL TISSUE; ARTICLE; CELL FREE SYSTEM; CHEMICAL REACTION KINETICS; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; ULTRAVIOLET RADIATION;

EID: 0345356572     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000003108748577     Document Type: Article

References (35)

1. Hockel, M.; Schlenger, K.; Mitze, M.; Schaffer, U.; Vaupel P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 6:3-9; 1996.
2. Siemann, D. W. Modification of chemotherapy by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys. 10:1585-1594; 1984.
3. Grau, C.; Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol. 13:301-309; 1988.
4. De Jaeger, K.; Kavanagh, M. C.; Hill, R. P. Relationship of hypoxia to metastatic ability in rodent tumours. Br. J. Cancer 84:1280-1285; 2001.
5. Semenza, G. L. Regulation of hypoxia-induced angiogenesis: A chaperone escorts VEGF to the dance. J. Clin. Invest. 108:39-40; 2001.
6. Hockel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schaffer, U.; Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509-4515; 1996.
7. Brown, J. M. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol. Med. Today 6(4):157-162; 2000.
8. Xu, G.; McLeod, H. L. Strategies for enzyme/prodrug cancer therapy [Review]. Clin. Cancer Res. 7(11)3314-3324; 2001.
9. Waxman, D. J.; Chen, L.; Hecht, J. E.; Jounaidi, Y. Cytochrome P450-based cancer gene therapy: Recent advances and future prospects. Drug Metab. Rev. 31:503-522; 1999.
10. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res. 12:185-192; 2000.
11. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol. Res. 12:325-333; 2000.
12. Blumenthal, R. D.; Taylor, A.; Osorio, L.; Ochakovskaya, R.; Raleigh, J. ; Papadopoulou, M.; Bloomer, W. D.; Goldenberg, D. M. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int. J. Cancer 94:564-571; 2001.
13. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cis-DDP and cyclophosphamide in vivo. Int. J. Radiat. Oncol. Biol. Phys. 42:775-779; 1998.
14. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother. Pharmacol. 48(2):160-168; 2001.
15. Papadopoulou, M. V.; Ji, M.; Ji, X.; Bloomer, W. D. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo. Comparison with tirapazamine. Cancer Chem. Pharmacol. 50:291-298; 2002.
16. Papadopoulou, M. V.; Ji, M.; Ji, X.; Bloomer, W. D. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo. Comparison with tirapazamine. Oncol. Res. 13:47-54; 2002.
17. Papadopoulou, M. V.; Ji, M.; Ji, X.; Bloomer, W. D.; Hollingshead, M. G. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chem. Pharmacol. 50:501-508; 2002.
18. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D.; Hollingshead, M. G. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J. Exp. Ther. Oncol. 2(5):298-305; 2002
19. Papadopoulou, M. V.; Ji, X.; Bloomer, W. D. Hypoxia-dependent retinal toxicity of NLCQ-1 and tirapazamine in BALB/c mice. Proc. Am. Assoc. Cancer Res. Annu. Meet. 43:1092; 2002.
20. Papadopoulou, M. V.; Ji, X.; Xue, C.; Bloomer, W. D. In vitro schedule-dependent potentiation of taxol, 5FU and cisDDP by the hypoxic cytotoxin NLCQ-1. Comparison with tirapazamine. 11th Int. Conference on Chemical Modifiers of Cancer treatment. Tumor Physiology and Cancer Treatment. Banff, Alberta, Canada (Proceedings), October 5-7, 2000.
21. Kamath, S. A.; Rubin, E. Interaction of calcium with microsomes: A modified method for the rapid isolation of rat liver microsomes. Biochem. Biophys. Res. Commun. 49:52-59; 1972.
22. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254; 1976.
23. Barham, H. M.; Stratford, I. J. Enzymology of the reduction of the novel fused pyrazine mono-N-oxide bioreductive drug, RB90740. Roles for P450 reductase and cytochrome b5 reductase. Biochem. Pharmacol. 51:829-837; 1996 (and references cited therein).
24. Reid, J. M.; Squillace, D. P.; Ames, M. M. Single dose C pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2FI Mice. Cancer Chem. Pharmacol. 51:483-487; 2003.
25. Robertson, N.; Haigh, A.; Adams, G. E.; Stratford, I. J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer 30A:1013-1019; 1994.
26. Hodnick, W. F.; Sartorelli, A. C. Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res. 53:4907-4912; 1993.
27. McClelland, R. A.; Panicucci, R.; Rauth, A. M. Products of the reduction of 2-nitroimidazoles. J. Am. Chem. Soc. 109:4308-4313; 1987.
28. Noss, M. B.; Panicucci, R.; McClelland, R. A.; Rauth, A. M. Preparation, toxicity and mutagenicity of 1-methyl-2-nitrosoimidazole: A toxic 2-nitroimidazole reduction product. Biochem. Pharmacol. 37:2585-2593; 1988.
29. Workman, P. Keynote address: Bioreductive mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 22:631-637; 1992.
30. Walton, M. I.; Wolf, C. R.; Workman, P. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int. J. Radiat. Oncol. Biol. Phys. 16:983-986; 1989.
31. Joseph, P.; Jaiswal, A. K.; Stobbe, C. C.; Chapman, J. D. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys. 29:351-355; 1994.
32. Lloyd, R. V.; Dulling, D. R.; Rumyantseva, G. V.; Mason, R. P.; Bridson, P. K. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol. Pharmacol. 40:440-445; 1991.
33. Vromans, R. M.; van der Straat, R.; Groeneveld, M.; Vermeulen, N. P. E. One electron reduction of mitomycin c by rat liver: Role of cytochrome P450 and NADPH-cytochrome P450 reductase. Xenobiotica 20:967-978; 1990.
34. Bailey, S. M.; Lewis, A. D.; Workman, P. Involvement of NADPH:cytochrome P450 in activation of EO9 to a DNA damaging species. Br. J. Cancer 69(Suppl. XXI):57; 1994.
35. Tomigahara, Y.; Onogi, M.; Saito, K.; Isobe, N.; Kaneko, H.; Nakatsuka, I. Metabolism of cyanox in rat. II. Sex-related differences in oxidative dearylation and disulphuration. Xenobiotica 30(4):395-406; 2000.